BioSyent Inc.RX.V

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX-V · Canada · biosyent.com

BioSyent Inc. is a Canadian specialty healthcare company that acquires, licenses, develops, and commercializes pharmaceutical and other healthcare products in Canada and internationally. The company's portfolio includes FeraMAX (iron deficiency anemia treatment), Tibella (hormone replacement therapy), RepaGyn, Cathejell, and Proktis-M, with a focus on innovative products sourced through international partnerships that offer therapeutic advantages and defensible intellectual property.

Key ratios

Operating cash flow growth

-3.9%TTM

2025 4.0%2024 71.4%2023 2.2%

EPS growth

20.4%TTM

2025 27.1%2024 16.0%2023 22.1%

FCF / Sales

20.6%TTM

2025 20.8%2024 24.6%2023 15.8%

Net margin

17.7%TTM

2025 20.9%2024 20.8%2023 20.5%

ROA

15.9%TTM

2025 15.4%2024 13.9%2023 11.4%

ROE

23.7%TTM

2025 23.6%2024 20.8%2023 19.0%

Revenue growth

20.1%TTM

2025 22.9%2024 10.9%2023 13.1%

Recent news

Track RX.V in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer